Tech Company Financing Transactions
Ocugen Funding Round
Ocugen secured a $30 million funding round on 11/7/2024. Investors included Avenue Capital.
Transaction Overview
Company Name
Announced On
11/7/2024
Transaction Type
Debt
Amount
$30,000,000
Round
Undisclosed
Investors
Avenue Capital (Chad Norman)
Proceeds Purpose
Proceeds from the facility are intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5 Great Valley Pkwy. 160
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway to treat sight threatening ocular disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shankar Musunuri
Chief Financial Officer
Sanjay Subramanian
Chief Medical Officer
Mohamed Genead
Chief Scientific Officer
Rasappa Arumugham
Controller
Jessica Crespo
VP - Regulatory Affairs
Vijay Tammara
Browse more venture capital transactions:
Prev: 11/7/2024: Knexus venture capital transaction
Next: 11/7/2024: Craftt venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs